Tumor Growth Inhibition and Survival Time of CT-26/tk-luc Tumor–Bearing BALB/c Mice (n = 12) After Intravenous Administration of Different Treatments
| Tumor growth inhibition | Survival time | ||||||
|---|---|---|---|---|---|---|---|
| Treatment | Mean growth inhibition rate (%) | Expected growth inhibition rate (%) | Combination index | P | Median survival time (d) | Increase in life span (%)* | P |
| 111In-vinorelbine liposomes | 69 | 67 | 1.06 | <0.01 | 35 | +46 | 0.0045 |
| Vinorelbine liposomes | 51 | – | – | <0.01 | 31 | +29 | 0.0136 |
| 111In-liposomes | 33 | – | – | <0.01 | 31 | +29 | 0.0083 |
| 111In-DOTA | 3 | – | – | NS | 28 | +17 | NS |
| NanoX liposomes | – | – | – | – | 24 | – | – |
↵* % increase in life span was expressed as (T/C-1) × 100%, where T is median survival time of treated mice, and C is median survival time of control mice.
NS = not significant.
Tumor growth tracing was measured twice per week using digital caliper. P values of survival time were determined by log-rank test.